Dyspnea is a complex subjective experience that is common in terminal illness. Patients may present at any time during the course of their illness, although prevalence increases with disease progression. Dyspnea has physical, psychological, social and spiritual components; without recognizing how each of these contributes to the total suffering of dyspnea, management is unlikely to be successful. The management of dyspnea involves both pharmacological and non-pharmacological treatment. The main pharmacological palliative treatments are oxygen, opioids, and benzodiazepines, but the evidence to support these treatments is limited. More research is urgently needed to establish the efficacy of current treatments and to identify new ones.
Get full access to this article
View all access options for this article.
References
1.
Stilbeck J, Mott L, Page H, et al: Palliative care in chronic obstructive airways disease: a needs assessment. Palliat Med. 1998;12:245-254.
2.
Krech RL, Davis J, Walsh D, et al: Symptoms of lung cancer. Palliat Med. 1992;6:309-315.
3.
McCarthy M, Lay M, Addington-Hall J: Dying from heart disease. J Roy Soc Phys. 1996;30:325-328.
4.
Motor Neurone Disease Association: Motor neurone disease-a problem solving approach. MNDA. 1996; 9-10.
5.
Addington-Hall J, Lay M, Altmann D, et al: Symptom control, communication with health professionals, and hospital care of stroke patients in the last year of life as reported by surviving family, friends and officials. Stroke. 1995;26:2242-2248.
6.
Comroe JH: Some theories of the mechanism of dyspnoea. In Howell JB, Campbell EJM (eds.): Breathlessness. Oxford, Blackwell Scientific Publications, 1966; 1-7.
7.
Rhoades R, Pflanzer R: Human Physiology. 3rd edition. London, Saunders College Publishing, 1996.
8.
Cockcroft A, Guz A: Breathlessness. Postgrad Med J. 1987;63:637-641.
9.
Wasserman K, Casaburi R: Dyspnea: physiological and pathophysiological mechanisms. Ann Rev Med. 1988;39:503-515.
Heyse-Moore LH: Respiratory symptoms. In Saunders C, Sykes N (eds.): The management of terminal malignant disease. 3rd edition. London, Edward Arnold, 1993; 76-94.
12.
Kemp C: Palliative care for respiratory problems in terminal illness. Am J Hosp and Pall Care. 1997;14:26-30.
13.
Burdon JGW, Juniper EF, Killian KJ, et al: The perception of breathlessness in asthma. Am Rev Respir Dis. 1982;126:825-828.
14.
Stoller JK, Ferranti R, Feinstein AR: Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis. 1986;135:1229-1233.
15.
Farncombe M, Charter S, Gillis A: The use of nebulised opioids for breathlessness: a chart review. Palliat Med. 1994;8:306-312.
16.
Simon PM, Schwartzstein RM, Weiss JW, et al: Distinguishable sensations of breathlessness induced in normal volunteers. Am Rev Respir Dis. 1989;140:1021-1027.
17.
Simon PM, Schwartzstein RM, Weiss JW, et al: Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990;142:1009-1014.
18.
Elliott MW, Adams L, Cockcroft A, et al: The language of breathlessness. Am Rev Respir Dis. 1991;144:826-832.
19.
Heyse-Moore LH: On dyspnoea in advanced cancer. DM thesis. Southampton, University of Southampton, 1993.
Corner J, Plant H, A’Hern R, et al: Nonpharmacological intervention for breathlessness in lung cancer. Palliat Med. 1996;10:299-305.
22.
Woodcock AA, Gross ER, Geddes DM: Oxygen relieves breathlessness in “pink puffers.”Lancet. 1981;i:907-909.
23.
Davidson AC, Leach R, George RJD, et al: Supplemental oxygen and exercise ability in chronic obstructive airway disease. Thorax. 1988;43:965-971.
24.
Swinburn CR, Mould H, Stone TN, et al: Symptomatic benefit of supplemental oxygen in hypoxaemic patients with chronic lung disease. Am Rev Respir Dis. 1991;143:913-915.
25.
Bruera E, de Stoutz M, Velasco-Leiva A, et al: Effects of oxygen on dyspnea in hypoxaemic terminal cancer patients. Lancet. 1993;342:13-14.
26.
Booth S, Kelly MJ, Cox NP, et al: Does oxygen help dyspnea in patients with cancer?Am J Respir Crit Care Med. 1996;153:1515-1518.
27.
Moore DP, Weston AR, Hughes JMB, et al: Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet. 1992;339:850-853.
28.
Liss HP, Grant BJB: The effect of nasal flow on breathlessness in patients with COPD. Ann Rev Respir Dis. 1988;137:1285-1288.
29.
Restrick LJ, Davis SW, Moore L: Ambulatory oxygen in chronic heart failure. Lancet. 1992;340:1192-1193.
30.
Schwartzstein RM, Lahive R, Pope A, et al: Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis. 1987;136:58-61.
31.
Spence DP, Graham DR, Ahmed J, et al: Does cold air affect exercise capacity and dyspnea in stable chronic obstructive airways disease?Chest. 1993;103:693-696.
32.
Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease. Ann Intern Med. 1980;93:391-398.
33.
Medical Research Council Working Group: Long term domicillary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis emphysema. Lancet. 1981;I:681-685.
34.
Bazuaye EA, Stone TN, Corris PA, et al: Variability in inspired oxygen concentrations with nasal cannulae. Thorax. 1992;47:609-611.
35.
Costello RW, Liston R, McNicholas WT: Compliance at night with low flow oxygen therapy; a comparison of nasal cannulae and venturi face masks. Thorax. 1995;50:405-406.
36.
Santiago TV, Remolina C, Scoles V, et al: Endorphins and the control of breathing: Ability of naloxone to restore flow-resistive load compensation in chronic obstructive pulmonary disease. N Engl J Med. 1981;304:1190-1195.
37.
Weil JV, McCullough RE, Kline JS, et al: Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med. 1975;292:1103-1106.
38.
Santiago TV, Johnson J, Riley DJ, et al: Effects of morphine on ventilatory response to exercise. J Appl Physiol. 1979;47:112-118.
39.
Reisine T, Pasternak G: Opioid analgesics and antagonists. In Hardman JG, Limbird LE (eds.): The pharmacological basis of therapeutics. 9th edition. London, McGraw Hill, 1996; 521-555.
40.
Wilson RH, Hoseth W, Dempsey ME: Respiratory acidosis: effects of decreasing respiratory minute volume in patients with chronic pulmonary emphysema with specific reference to oxygen, morphine and barbiturates. Am J Med. 1954;17:464-470.
41.
Woodcock AA, Gross ER, Gellert A, et al: Effects of dihydrocodeine, alcohol and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med. 1981;305:1611-1616.
42.
Johnson MA, Woodstock AA, Geddes DM: Dihydrocodeine for breathlessness in “pink puffers.”BMJ. 1983;286:675-677.
43.
Robin ED, Burke CM: Single-patient randomised clinical trial. Opiates for intractable dyspnea. Chest. 1986;90:888-892.
44.
Light RW, Muro JR, Sato RI, et al: Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;139:126-133.
45.
Rice KL, Kronenberg RS, Hedemark LL, et al: Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest. 1987;81:287-292.
46.
Eiser N, Denman WT, West C, et al: Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in pink puffer syndrome. Eur Resp J. 1991;4:926-931.
47.
Woodcock AA, Johnson MA, Geddes DM: Breathlessness, alcohol and opiates. N Engl J Med. 1982;306:1363-1364.
48.
Bruera E, MacMillan K, Pither J, et al: Effects of morphine on the dyspnea of terminal cancer patients. J Pain Symptom Manage. 1990;5:341-344.
49.
Bruera E, MacEachern T, Ripamonti C, et al: Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med. 1993;119:906-907.
50.
Cohen MH, Johnston-Anderson A, Krasnow SH, et al: Continuous intravenous infusion of morphine for severe dyspnoea. Southern Medical Journal. 1991;84:229-234.
51.
Boyd KJ, Kelly M: Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med. 1997;11:277-281.
52.
Shee CD: Palliation in chronic respiratory disease. Palliat Med. 1995;9:3-12.
53.
Rogers DF, Barnes PJ: Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet. 1989;i:930-931.
54.
Cabot PJ, Dodd PR, Cramond TR, et al: Characterisation of non conventional opioid binding sites in rat and human lung. Eur J Pharmacol. 1994;268:247-255.
55.
Young IH, Daviskas E, Keena VA: Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989;44:387-390.
56.
Farncombe M, Chater S: Case studies outlining use of nebulised morphine for patients with endstage chronic lung and cardiac disease. J Pain Symptom Manage. 1993;8:221-225.
57.
Beauford W, Saylor TT, Stansbury DW, et al: Effects of nebulised morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest. 1993;104:175-178.
58.
Davis CL, Hodder CA, Love S, et al: Effects of nebulised morphine and morphine-6-glucuronide on exercise endurance in patients with chronic obstructive airways disease. Thorax. 1994;49:393P.
59.
Masood AR, Reed JW, Thomas SHL: Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995;50:629-634.
60.
Davis CL, Penn K, A’Hern R, et al: Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Research Abstract from Palliative Care Research Forum 8-9, November 1995. Palliat Med. 1996;10:64.
61.
Leung R, Hill P, Burdon J: Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996;51:596-600.
62.
Zeppetella G: Nebulised morphine in the palliation of dyspnoea. Palliat Med. 1997: 11:267-275.
63.
Lang E, Jedeikin R: Acute respiratory depression as a complication of nebulised morphine. Can J Anaesth. 1998;45(1): 60-62.
64.
Ahmedzai S, Davis C: Nebulised drugs in palliative care. Thorax. 1997;52(Suppl 2): S75-S77.
Hanks GW, Trueman T, Twycross RG: Corticosteroids in terminal cancer: a prospective analysis of current practice. Postgrad Med J. 1983;59:702-706.
67.
Ahmedzai S: Palliation of respiratory symptoms. In Doyle D, Hanks GWC, MacDonald N (eds.): Oxford Textbook of Palliative Medicine. Oxford, OUP, 1998; 583-616.
68.
Demoly P, Chung KF: Pharmacology of corticosteroids. Resp Med. 1998;92:385-394.
69.
Weir DC, Robertson AS, Grove RI, et al: Time course of response to oral and inhaled corticosteroids in non-asthmatic chronic airflow obstruction. Thorax. 1990;45:118-121.
70.
Weissman DE, Dufer D, Vogel V, et al: Corticosteroid toxicity in neuro-oncology patients. J Neuro-Oncol. 1987;5:125-128.
71.
Rao S, Sherbaniuk RW, Prasad K, et al: Cardiopulmonary effects of diazepam. Clin Pharmacol Ther. 1973;14:182-189.
72.
Lakshminarayan S, Sahn SA, Hudson LD, et al: Effects of diazepam on ventilatory responses. Clin Pharmacol Ther. 1976;20:178-183.
73.
Mitchell-Heggs P, Murphy K, Minty K, et al: Diazepam in the treatment of dyspnoea in the “pink puffer” syndrome. Q J Med. 1980;49:9-20.
74.
Woodcock AA, Gross ER, Geddes DM: Drug treatment of breathlessness; contrasting effects of diazepam and promethazine in pink puffers. BMJ. 1981;283:343-346.
75.
Eimer M, Cable T, Gal P, et al: Effects of clorazepate on breathlessness and exercise tolerance in patients with chronic airflow obstruction. J Fam Pract. 1985;21:359-362.
76.
Man GCW, Hsu K, Sprouse BJ: Effect of aprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest. 1986;90:833-836.
77.
Greene JD, Pucino F, Carlson JD, et al: Effects of aprazolam on respiratory drive, anxiety and dyspnea in chronic airflow obstruction, a case study. Pharmacotherapy. 1989;9:34-38.
78.
Craven J, Sutherland A: Buspirone for anxiety disorders in patients with severe lung disease. Lancet. 1991;338:249.
79.
Garner SJ, Eldridge FL, Wagner PG, et al: Buspirone, an anxiolytic drug that stimulates respiration. Am Rev Respir Dis. 1989;139:946-950.
80.
Argyropoulou P, Patakas D, Koukou A, et al: Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respir. 1993;60:216-220.
81.
Matthay RA, Berger JH, Loke J: Effects of aminophylline on right and left ventricular performance in chronic obstructive pulmonary disease. Am J Med. 1978;64:903-910.
82.
Aubier M, Murciano D, Viires N, et al: Diaphragmatic contractility enhanced by aminophylline: role of extracelleular calcium. J Appl Physio. 1983;54:460-464.
83.
Murciano D, Aubier M, Lecocguic J, et al: Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med. 1984;311:349-353.
84.
Mahler DA, Matthay RA, Snyder PE, et al: Sustained-release theophylline reduces dyspnea in non-reversible obstructive airways disease. Am Rev Respir Dis. 1985;131:22-25.
85.
Chrystyn H, Mulley BA, Paeke MD: Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ. 1988;297:1606-1610.
86.
Rees PJ: Theophyllines in the treatment of asthma. B J Clin Pharm. 1991;45:9-10.
87.
British National Formulary. Number 35. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 1988.
88.
O’Neill PA, Morton PB, Stark RD: Chlorpromazine: a specific effect on breathlessness?Br J Clin Pharm. 1985;19:793-797.
89.
Ventafridda V, Spoldi E, De Conno F: Control of dyspnea in advanced cancer patients. Chest. 1990;6:1544-1545.
90.
Ahmedzai S, Carter R, Mills RJ, et al: Effects of nabilone on pulmonary function. Marihuana 1984: Proceedings of the Oxford symposium on Cannabis. Oxford, IRL Press, 1984; 371-378.
91.
Vachon L, Fitzgerald MX, Solliday NH, et al: Single dose effect of marihuana smoke. N Engl J Med. 1973;288:985-989.
92.
O’Neill PA, Stark RD, Morton PB: Do prostaglandins have a role in breathlessness?Am Rev Respir Dis. 1985;132:22-24.
93.
Bianco S, Vaghi A, Robuschi M, et al: Prevention of exercise induced bronchoconstriction by inhaled frusemide. Lancet. 1988;2:252-255.
94.
Stone P, Kurowska A, Tookman A: Nebulised frusemide for dyspnoea. Palliat Med. 1994;8:258.
95.
Winning AJ, Hamilton RD, Shea SA, et al: The effect of airway anaesthesia on the control of breathing and the sensation of breathlessness in man. Clin Sci. 1985;68:215-225.
96.
Winning AJ, Hamilton RD, Guz A: Ventilation and breathlessness on maximal exercise in patients with interstitial lung disease after local anaesthetic aerosol inhalation. Clin Sci. 1988;74:275-281.
97.
Damluji S: The effect of ventilatory stimulation with medroxyprogesterone on exercise performance and the sensation of dyspnoea in hypercapnic chronic bronchitis. Br J Dis Chest. 1986;80:273-279.
98.
Mikami M, Tatsumi K, Kimura H, et al: Respiration effect of synthetic progestin in small doses in normal men. Chest. 1989;96:969-970.
99.
Wilcock A, Corcoran R, Tattersfield AE: Safety and efficacy of nebulised lignocaine in patients with cancer and breathlessness. Palliat Med. 1994;8:35-38.
100.
Howard P, Clayton RM, Brennan SR, et al: Lignocaine aerosol and persistent cough. B J Dis Chest. 1977;71:19-24.
101.
O’Neill PA, Stretton TB, Stark RD, et al: The effect of indomethacin on breathlessness in patients with diffuse parenchymal disease of the lung. B J Dis Chest. 1986;80:72-79.
102.
Schiffman GL, Stansbury DW, Fischer CE, et al: Indomethacin and perception of dyspnea in chronic airflow obstruction. Am Rev Respir Dis. 1988;137:1094-1098.
103.
Working Party on Clinical Guidelines in Palliative Care. Changing gear: Guidelines for managing the last days of life in adults. London, The National Council for Hospice and Specialist Palliative Care, 1997.
104.
Twycross RG, Lichter I: The terminal phase. In Doyle D, Hanks GWC, MacDonald N (eds.): Oxford Textbook of Palliative Medicine. Oxford, OUP, 1998; 977-992.
105.
Higginson I, McCarthy M: Measuring symptoms in terminal cancer: are pain and dyspnoea controlled?J Roy Soc Med. 1989;82:264-267.
